Transaction · 0001213900-26-106531

Gabay Avraham

Gabay Avraham, CFO, reported an open-market or private sale at ORAMED PHARMACEUTICALS INC. involving 20000.000000 shares for an estimated $90200.00. Reported holdings after the transaction were 861076.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCFO
ORMPORAMED PHARMACEUTICALS INC.
Filing timeOct 02
Trade dateOct 01, 2026
Filing · SECView on SEC
InsiderProfile
% of reported position traded2.27%Shares sold ÷ (holdings after + shares sold). Estimated position before: 881,076 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$4.49
Pre-filing
1mo ago +12.9%1w ago +12.9%1d ago +4.0%
Returns since
7d30d90d180d1y

ORMP price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
ORMP since 2026-10-02Filed yesterday · 1 day of post-filing data
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001213900-26-106531
Common Stock
Transaction date
Oct 01, 2026
Filed Oct 02, 2026, 09:19 PM · 1d delay
Shares
20.0k sh
$4.51 per share
Estimated value
-$90.2k
Computed from shares × price
Holdings after
861k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Direct Ownership 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Financial Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.

  2. F2

    The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.440 to $4.650, inclusive. The Reporting Person undertakes to provi…

Original filing · 0001213900-26-106531
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

ORMP